Clinical features of patients who were responding to BNZ-1
| Patient . | Dose (mg/kg) . | STAT3 mutation . | Indication . | Prior treatment . | Baseline ANC . | Baseline HgB (g/dL) . | ANC best response . | HgB best response . | Overall response . | LTE (Y/N) . |
|---|---|---|---|---|---|---|---|---|---|---|
| L-OSU-004 | 1 | STAT3; p.Y640F, c.1919 A>T | Neutropenia, Infection | None (for LGL); abatacept for RA | 490 | 11.5 | 2230 (D28) | 12.1 | PR | N |
| L-OSU-006 | 2 | WT | Transfusion-dependent anemia, neutropenia | MTX | 580 | 9.2 | 3850 (D28) | 8.4 (stable) | PR | Y |
| L-UVA-004 | 2 | WT | Transfusion-dependent anemia | MTX, Cytoxan+pred, CsA, alemtuzumab | 430 | 7.7 | 880 (LTE WK 22) | 10.5 (LTE WK 9) | PR | Y |
| L-UVA-007 | 4 | D661Y | Transfusion-dependent anemia | MTX | 1140 | 10.4 | 2810 (WK 10) | 10.9 (WK 8) | PR | Y |
| Patient . | Dose (mg/kg) . | STAT3 mutation . | Indication . | Prior treatment . | Baseline ANC . | Baseline HgB (g/dL) . | ANC best response . | HgB best response . | Overall response . | LTE (Y/N) . |
|---|---|---|---|---|---|---|---|---|---|---|
| L-OSU-004 | 1 | STAT3; p.Y640F, c.1919 A>T | Neutropenia, Infection | None (for LGL); abatacept for RA | 490 | 11.5 | 2230 (D28) | 12.1 | PR | N |
| L-OSU-006 | 2 | WT | Transfusion-dependent anemia, neutropenia | MTX | 580 | 9.2 | 3850 (D28) | 8.4 (stable) | PR | Y |
| L-UVA-004 | 2 | WT | Transfusion-dependent anemia | MTX, Cytoxan+pred, CsA, alemtuzumab | 430 | 7.7 | 880 (LTE WK 22) | 10.5 (LTE WK 9) | PR | Y |
| L-UVA-007 | 4 | D661Y | Transfusion-dependent anemia | MTX | 1140 | 10.4 | 2810 (WK 10) | 10.9 (WK 8) | PR | Y |
CsA, cyclosporine; EO; end of treatment; HgB, hemoglobin; MTX, methotrexate; pred, prednisone; RA, rheumatoid arthritis; WT, wild-type.